Table 1.
Characteristics of the studies included in the meta-analysis.
| Author | Year | Area | Follow-up (months) | Treatment | No. of patients | Stage | Cut-off value | Survival analysis | Analysis |
|---|---|---|---|---|---|---|---|---|---|
| Buettner | 2018 | Multicenter | 29 (4.8-53.3) | Surgery | 991 | NA | 190 | OS | UV |
| Chen | 2015 | China | 57.8±11.2 | Surgery | 322 | Mixed | 123 | OS/RFS | MV |
| Cho | 2018 | Korea | 25 (19.6-30.4)) | Chemotherapy | 257 | Metastatic | 123.8 | OS/PFS | UV |
| Hu | 2018 | China | NA | Surgery | 173 | Mixed | 150 | OS | UV |
| Kitano | 2017 | Japan | NA | Mixed | 120 | Mixed | 185 | OS/RFS | MV |
| Ramen | 2018 | China | NA | Surgery | 90 | NA | 148 | OS/RFS | MV |
| Saito | 2015 | Japan | 70 (42-82) | Surgery | 121 | Mixed | 150 | OS | MV |
| Yoh | 2017 | Japan | 65 (26-84) | Surgery | 134 | Mixed | 120 | OS | MV |
| Zhang | 2016 | China | NA | NA | 187 | Mixed | 138 | OS | MV |
OS: overall survival; PFS: progress-free survival; RFS: recurrence-free survival; UV: univariate; MV: multivariate; NA: not available.